https://onlinelibrary.wiley.com/doi/full/10.1111/imj.11_14849 (It's free access but I think it's just a poster) Jorge do Campo 1 and Vivienne Taylor 2 1 Noosa Hospital, Queensland, Australia 2 Ibuki Medical Centre, Noosa, Queensland, Australia Abstract Background: Epstein Barr Virus (EBV) is a widely disseminated herpes virus (human herpes virus4). The majority of primary EBV infections in humans are thought to be originate in the oropharynx. Oropharyngeal epithelial cells are permissive for viral replication. EBV is the etiologic agent of infectious mononucleosis. The host cells of EBV are the B and T Lynphocytes. The EBV persist as a latent asymptomatic infection for life in adults and is associated to B cell Lymphoma, T cell lymphoma, Hodgkin lymphoma, Burkit‐lymphoma and Naso‐pharyngeal carcinoma. The EBV has been implicated in the pathogenesis of MS as high EBV titres have been reported in patients with MS. Patients with positive EBV serology and CFS could be considered as carriers of a chronic infection related to EBV. In patients with CFS positive levels of EBV antibody have been reported but there is no definitive evidence that chronic EBV infection is responsible for the symptoms. Spironolactone has an antivirus effect against EBV by inhibiting EBV SM protein function. The present report is related to a group of patients with Chronic Fatigue Syndrome (CFS) and positive serology for EBV who voluntarily decided to try low dose Spironolactone for their condition. Population and Method: 21 patients with positive serology for EBV infection and CFS were included All the patients were treated with multi‐vitamins. Patients were invited and educated about potential benefit and adverse effects of Spironolactone; patients started Spironolactone at dose of 12.5 mg to 25 mg a day. Results: 21 Patients seventeen Females age 54.2 +11, four Males 63.7+5. All the patients had multivitamins and Spironolactone. Five patients presented intolerance to Spironolactone. 16 tolerated the dose of 25 mg a day 5 of these patients had no more CFS and all the rest improve in fatigue and general symptoms. Conclusion: The EBV positive serology should not be ignore when associated with CFS it could represent a latent chronic infection. The Spironolactone treatment will open a perspective of new antiviral drugs. In this group of patients has demonstrated improvement in general condition and some of them had no more fatigue.